ETON  Pharmaceuticals Inc

After years of being “just a pipeline story”, Eton has transitioned into a small but diversified rare-disease platform with multiple approved assets and a focused late-stage pipeline anchored by ET-400 and ET-600.

AQST & PHAR -Countdown Jan 31 PDUFA

We are on Friday, January 23, 2026 (Italy time). For January, in your catalyst tracker there are essentially two PDUFAs still “missing” that matter for this piece: Aquestive (AQST) with Anaphylm and Pharming (PHAR) with the pediatric Joenja sNDA (4–11 years, APDS). Both currently carry a PDUFA target action date of January 31, 2026.

Space Defence & AI

When you line up the numbers on artificial intelligence in space operations, autonomous systems and new-generation missile defence, it becomes very clear we are not looking at a “nice theme” to trade for a few quarters. We are watching the birth of a structural, AI-native arms race that stretches easily over the next 20–30 years.

KPTI Karyopharm Therapeutics

At the dawn of 2026, Karyopharm Therapeutics stands at a critical inflection point that will determine not only near-term share performance, but in many respects the long-term viability of the company. After spending the last five years building a commercial foothold in late-line relapsed/refractory multiple myeloma, Karyopharm has repositioned the selinexor franchise toward two potentially transformative Phase 3 readouts: the SENTRY trial in myelofibrosis and the XPORT-EC-042 trial in endometrial cancer maintenance.

IONS Ionis Pharmaceuticals

Ionis is one of the long-standing pioneers of antisense oligonucleotide (ASO) therapeutics. Founded in 1989, the company has taken antisense from a controversial idea to an approved therapeutic class with multiple marketed products and a deep late-stage pipeline.

HELP Helus Pharma Inc

Helus Pharma is the new brand for Cybin, now trading under the ticker HELP on the Nasdaq Global Market and on Cboe Canada. The company is trying to position itself as a “psychedelic 2.0” / mental-health pure play, built around proprietary novel serotonergic agonists (NSAs) rather than classic psychedelic molecules

BMEA Biomea Fusion Inc

bmea2

Biomea Fusion has quietly morphed from an oncology story into a pure diabetes and obesity medicines company, with a potentially first-in-class oral menin inhibitor (icovamenib) for insulin-deficient type 2 diabetes and an oral GLP-1 receptor agonist (BMF-650) aimed at obesity. 2026 is all about execution: Phase II programs in T2D, first human weight-loss data for BMF-650 and a cash runway that, after the 2025 down-rounds and cost cuts, now stretches into 2027.

FULC Fulcrum Therapeutics Inc

This note is a follow-up to the previous Merlintrader deep dive on Fulcrum Therapeutics (link to the earlier report). Since then, Fulcrum has reshaped its story around pociredir, an oral HbF inducer for sickle cell disease (SCD), delivered a series of positive PIONEER data updates and, crucially, raised fresh capital to extend runway well beyond the next set of readouts.

ALT Altimmune Inc

As of the afternoon session on 21 January 2026, Altimmune is trading around 4.5–4.6 USD, up roughly 9% versus the prior close. Volumes are clearly above a quiet day but not at “capitulation” or “meme-stock” levels. There is no new 8-K or press release dated today, and the official IR feed has not dropped fresh clinical or corporate news.

NVAX Novavax and Pfizer

The short version: Novavax is no longer just fighting for survival as a COVID single-product story. With Sanofi first and Pfizer now, Matrix-M is slowly turning into a royalty platform. The balance sheet is still tight and the story remains binary, but the “all-or-nothing” risk has shifted a bit more towards “long-duration option on partner execution”.

GUTS Fractyl Health Inc Update jan 20

Fractyl Health is a small-cap metabolic therapeutics company listed on Nasdaq under the ticker GUTS. The company’s core bet is that a one-time endoscopic procedure on the duodenum, combined eventually with gene therapy, can offer a durable “off-ramp” for patients who need or want to come off GLP-1 drugs but would otherwise regain weight quickly.

US Airline Sector 2026

The U.S. airline sector in early 2026 is the product of two overlapping cycles. The first is the post-COVID recovery wave: a violent rebound in demand, especially leisure and international, that allowed the big carriers to refill their cash tanks, repair balance sheets and renegotiate labor. The second is the return of classic airline constraints: high capital intensity, structurally volatile fuel costs, periodic labor shocks and the need to keep debt under control without sacrificing network relevance.

SHPH Shuttle Pharmaceuticals Holdings Inc

The 2026 biotech landscape is increasingly bifurcated between traditional development stories and “tech-bio” platforms that use AI to de-risk and compress timelines. Shuttle Pharmaceuticals positions itself at this intersection: a small oncology company built around radiosensitizers and a newly acquired AI platform, Molecule.ai, targeting the problem of radio-resistant tumors and inefficient drug development.

CRVS Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is a clinical-stage biotech now almost entirely defined by soquelitinib, an oral, highly selective ITK inhibitor designed to “rebalance” T-cell responses. The drug sits at the intersection of two very different but complementary franchises: inflammatory skin disease (atopic dermatitis) and T-cell lymphomas (PTCL and related entities).